Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease

Vasilios G AthyrosAristotle University of Thessaloniki, Hippocration Hospital, Medical School, 2nd Department of Internal Medicine, Thessaloniki, Greece+0030 2310 892606; +0030 2310 445220; [email protected]

, MD FESC FASA FRSPH FACS FASAB,

Niki KatsikiAristotle University of Thessaloniki, Hippocration Hospital, Medical School, 2nd Department of Internal Medicine, Thessaloniki, Greece+0030 2310 892606; +0030 2310 445220; [email protected]

Asterios KaragiannisAristotle University of Thessaloniki, Hippocration Hospital, Medical School, 2nd Department of Internal Medicine, Thessaloniki, Greece+0030 2310 892606; +0030 2310 445220; [email protected]

Bibliography

Eguchi A, Povero D, Alkhouri N, Feldstein AE. Novel therapeutic targets for nonalcoholic fatty liver disease. Expert Opin Ther Targets 2013;17(7):773-9
Web of Science ®Google Scholar
Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006;22:873-83
PubMed Web of Science ®Google Scholar
Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011;7:796-805
PubMed Web of Science ®Google Scholar
Athyros VG, Tziomalos K, Gossios TD, GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22
PubMed Web of Science ®Google Scholar
Kargiotis K, Katsiki N, Athyros VG, et al. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia. A preliminary report. Curr Vasc Pharmacol 2013; In press
Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date